HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Lowers Price Target to $37
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Viridian Therapeutics (NASDAQ:VRDN) but lowers the price target from $40 to $37.
August 10, 2023 | 10:32 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a 'Buy' rating on Viridian Therapeutics but lowers the price target from $40 to $37.
The news is directly related to Viridian Therapeutics and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowering of the price target may indicate a slightly less optimistic outlook for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100